ID   HTC-C3
AC   CVCL_1295
SY   HTC/C3; HTC C3; HTCC3
DR   BTO; BTO:0006211
DR   CLO; CLO_0037152
DR   CLO; CLO_0050946
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN01821636
DR   BioSample; SAMN01821686
DR   BioSample; SAMN03470940
DR   cancercelllines; CVCL_1295
DR   Cell_Model_Passport; SIDM00496
DR   CGH-DB; 58-1
DR   ChEMBL-Cells; CHEMBL3308747
DR   ChEMBL-Targets; CHEMBL1075472
DR   Cosmic; 924151
DR   Cosmic; 2009524
DR   Cosmic; 2054084
DR   Cosmic; 2613249
DR   Cosmic-CLP; 924151
DR   DepMap; ACH-001350
DR   DSMZ; ACC-580
DR   DSMZCellDive; ACC-580
DR   EGA; EGAS00001000978
DR   GDSC; 924151
DR   GEO; GSM1669916
DR   IARC_TP53; 1306
DR   JCRB; JCRB0164
DR   JCRB; FDSC0042
DR   LINCS_LDP; LCL-1689
DR   PharmacoDB; HTCC3_633_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1295
DR   RCB; RCB0452
DR   Wikidata; Q54896604
RX   PubMed=1516062;
RX   PubMed=2196988;
RX   PubMed=9177455;
RX   PubMed=16924234;
RX   PubMed=20164919;
RX   PubMed=23833040;
RX   PubMed=25877200;
RX   PubMed=27397505;
RX   PubMed=30737244;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: ~100 hours (DSMZ=ACC-580); ~2 days (Note=Lot 04162002) (JCRB=JCRB0164).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro152Leu (c.455C>T); ClinVar=VCV000142766; Zygosity=Homozygous (PubMed=1516062; PubMed=30737244; Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.77%; Native American=0.3%; East Asian, North=74.17%; East Asian, South=22.11%; South Asian=0.65%; European, North=0.12%; European, South=1.88% (PubMed=30894373).
CC   Discontinued: JCRB; FDSC0042; true.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): Cosmic-CLP; DSMZ; JCRB; PubMed=25877200; PubMed=30737244; RCB
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 10,12
ST   D16S539: 9,12
ST   D18S51: 14,17
ST   D19S433: 14
ST   D21S11: 29,30
ST   D2S1338: 17,23
ST   D3S1358: 16
ST   D5S818: 11,12
ST   D7S820: 11,12
ST   D8S1179: 12,14
ST   FGA: 21,22
ST   Penta D: 9
ST   Penta E: 11,16
ST   TH01: 6,7
ST   TPOX: 8,9
ST   vWA: 14,15
DI   NCIt; C3878; Thyroid gland anaplastic carcinoma
DI   ORDO; Orphanet_142; Anaplastic thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   44Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 41
//
RX   PubMed=1516062;
RA   Yoshimoto K., Iwahana H., Fukuda A., Sano T., Saito S., Itakura M.;
RT   "Role of p53 mutations in endocrine tumorigenesis: mutation detection
RT   by polymerase chain reaction-single strand conformation
RT   polymorphism.";
RL   Cancer Res. 52:5061-5064(1992).
//
RX   PubMed=2196988; DOI=10.1002/1097-0142(19900501)65:9<1971::AID-CNCR2820650916>3.0.CO;2-V;
RA   Enomoto T., Sugawa H., Inoue D., Miyamoto M., Kosugi S., Takahashi T.,
RA   Kitamura N., Yamamoto I., Konishi J., Mori T., Imura H.;
RT   "Establishment of a human undifferentiated thyroid cancer cell line
RT   producing several growth factors and cytokines.";
RL   Cancer 65:1971-1979(1990).
//
RX   PubMed=9177455; DOI=10.1016/S0304-3835(97)04742-3;
RA   Satake S., Sugawara I., Watanabe M., Takami H.;
RT   "Lack of a point mutation of human DNA topoisomerase II in
RT   multidrug-resistant anaplastic thyroid carcinoma cell lines.";
RL   Cancer Lett. 116:33-39(1997).
//
RX   PubMed=16924234; DOI=10.1038/sj.onc.1209899;
RA   Yu W., Imoto I., Inoue J., Onda M., Emi M., Inazawa J.;
RT   "A novel amplification target, DUSP26, promotes anaplastic thyroid
RT   cancer cell growth by inhibiting p38 MAPK activity.";
RL   Oncogene 26:1178-1187(2007).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=23833040; DOI=10.1210/jc.2013-2383;
RA   Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M.,
RA   Ibrahimpasic T., Ghossein R.A., Fagin J.A.;
RT   "Frequent somatic TERT promoter mutations in thyroid cancer: higher
RT   prevalence in advanced forms of the disease.";
RL   J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. III, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//